CN Patent

CN108395437B — 氘代化合物及其医药用途

Assigned to Beijing Junke Huayuan Pharmaceutical Technology Co ltd · Expires 2020-04-14 · 6y expired

What this patent protects

本发明涉及结构式I所代表的化合物及其非毒性药学上可接受的盐： 式I中，R1为H，CH 3 或氘代甲基(CD 3 )；R2为CH 3 或CH 2 CH 3 ；R3、R4和R5分别独立地为H或氘(D)；当R1为H或CH 3 时，R3、R4和R5必须至少有一个为D。

USPTO Abstract

本发明涉及结构式I所代表的化合物及其非毒性药学上可接受的盐： 式I中，R1为H，CH 3 或氘代甲基(CD 3 )；R2为CH 3 或CH 2 CH 3 ；R3、R4和R5分别独立地为H或氘(D)；当R1为H或CH 3 时，R3、R4和R5必须至少有一个为D。

Drugs covered by this patent

Patent Metadata

Patent number
CN108395437B
Jurisdiction
CN
Classification
—
Expires
2020-04-14
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Junke Huayuan Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.